- Home
- FGEN vs CGTX Comparison
FGEN vs CGTX Comparison
Compare FGEN & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FGEN
- CGTX
- Stock Information
- Founded
- FGEN 1993
- CGTX 2007
- Country
- FGEN United States
- CGTX United States
- Employees
- FGEN N/A
- CGTX N/A
- Industry
- FGEN Biotechnology: Pharmaceutical Preparations
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- FGEN Health Care
- CGTX Health Care
- Exchange
- FGEN Nasdaq
- CGTX Nasdaq
- Market Cap
- FGEN 33.5M
- CGTX 25.1M
- IPO Year
- FGEN 2014
- CGTX 2021
- Fundamental
- Price
- FGEN $7.26
- CGTX $0.57
- Analyst Decision
- FGEN Strong Buy
- CGTX Strong Buy
- Analyst Count
- FGEN 1
- CGTX 4
- Target Price
- FGEN $250.00
- CGTX $2.83
- AVG Volume (30 Days)
- FGEN 74.7K
- CGTX 17.0M
- Earning Date
- FGEN 08-05-2025
- CGTX 08-07-2025
- Dividend Yield
- FGEN N/A
- CGTX N/A
- EPS Growth
- FGEN N/A
- CGTX N/A
- EPS
- FGEN N/A
- CGTX N/A
- Revenue
- FGEN $6,996,000.00
- CGTX N/A
- Revenue This Year
- FGEN N/A
- CGTX N/A
- Revenue Next Year
- FGEN N/A
- CGTX N/A
- P/E Ratio
- FGEN N/A
- CGTX N/A
- Revenue Growth
- FGEN N/A
- CGTX N/A
- 52 Week Low
- FGEN $4.50
- CGTX $0.22
- 52 Week High
- FGEN $38.25
- CGTX $2.54
- Technical
- Relative Strength Index (RSI)
- FGEN 60.54
- CGTX 63.33
- Support Level
- FGEN $5.37
- CGTX $0.52
- Resistance Level
- FGEN $5.73
- CGTX $1.04
- Average True Range (ATR)
- FGEN 0.49
- CGTX 0.09
- MACD
- FGEN 0.27
- CGTX 0.04
- Stochastic Oscillator
- FGEN 83.80
- CGTX 40.18
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.